Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23093781.
- Also identified by DOI 10.1172/JCI63170 and PMC identifier 3484444.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
DC-mediated NKT cell activation is critical in initiating the immune response following kidney ischemia/reperfusion injury (IRI), which mimics human acute kidney injury (AKI). Adenosine is an important antiinflammatory molecule in tissue inflammation, and adenosine 2A receptor (A₂AR) agonists protect kidneys from IRI through their actions on leukocytes. In this study, we showed that mice with A₂AR-deficient DCs are more susceptible to kidney IRI and are not protected from injury by A₂AR agonists. In addition, administration of DCs treated ex vivo with an A₂AR agonist protected the kidneys of WT mice from IRI by suppressing NKT production of IFN-γ and by regulating DC costimulatory molecules that are important for NKT cell activation. A₂AR agonists had no effect on DC antigen presentation or on Tregs. We conclude that ex vivo A₂AR-induced tolerized DCs suppress NKT cell activation in vivo and provide a unique and potent cell-based strategy to attenuate organ IRI.
Medical subject headings
- Acute Kidney Injury
- Adenosine A2 Receptor Agonists
- Dendritic Cells
- Immune Tolerance
- Kidney
- Receptor, Adenosine A2A